AstraZeneca
AZN
Market cap $226B

74.42 USD

-0.58

0.77%

At close Jun 13, 4:00 PM EDT

After hours

73.80

-0.62

0.83%

1 day

-0.77%

5 days

2.59%

1 month

9.89%

3 months

-2.73%

6 months

11.78%

Year to date

12.96%

1 year

-6.43%

5 years

41.38%

10 years

128.98%

About: A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

Employees: 94,300

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,296 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

191% more call options, than puts

Call options by funds: $855M | Put options by funds: $294M

62% more funds holding in top 10

Funds holding in top 10: 13 [Q4 2024] → 21 (+8) [Q1 2025]

58% more first-time investments, than exits

New positions opened: 147 | Existing positions closed: 93

40% more repeat investments, than reductions

Existing positions increased: 516 | Existing positions reduced: 368

9% more capital invested

Capital invested by funds: $34.1B [Q4 2024] → $37.3B (+$3.21B) [Q1 2025]

2% more funds holding

Funds holding: 1,202 [Q4 2024] → 1,222 (+20) [Q1 2025]

0.78% less ownership

Funds ownership: 33.12% [Q4 2024] → 32.35% (-0.78%) [Q1 2025]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for AZN.

See Analyst Rankings

Financial journalist opinion

Based on 27 articles about AZN published over the past 30 days

5 Ideal 'Safer' Dividend Buys From Bloomberg's June Watch List

I highlight 15 dividend-paying stocks from Bloomberg's 50 Companies to Watch that meet my 'safer' criteria: free cash flow yields exceed dividend yields. The top ten dividend focus stocks offer an estimated average net gain of 15.48% by June 2026, with diversified sector representation and generally lower volatility. Five stocks - China Hongqiao, ITV, Vodacom, Subsea 7, and Advanced Info - stand out as 'ideal' for income investors, combining safety and attractive yield-to-price ratios.

5 Ideal 'Safer' Dividend Buys From Bloomberg's June Watch List

Proactive Investors

AstraZeneca bets big on AI and China with $3.6bn CSPC collaboration

AstraZeneca PLC (LSE:AZN) is betting big on AI-enabled drug discovery (and China), agreeing a research collaboration with China's CSPC Pharmaceutical Group that could see the Anglo-Swedish drugmaker pay up to $3.6 billion in milestone payments. The deal focuses on developing new oral treatments for chronic conditions, with both companies contributing to the discovery and development of pre-clinical candidates.

AstraZeneca bets big on AI and China with $3.6bn CSPC collaboration

AstraZeneca Teams Up With CSPC Pharmaceuticals With Deal Valued at Up to $5.33 Billion

The deal with China's CSPC Pharmaceuticals, focused on AI-driven research, aims to advance the discovery and development of new drug candidates.

AstraZeneca Teams Up With CSPC Pharmaceuticals With Deal Valued at Up to $5.33 Billion

AstraZeneca agrees to research deal worth up to $5.22 billion with CSPC

AstraZeneca said on Friday it has agreed to a research deal with Chinese drugmaker CSPC Pharmaceuticals worth up to $5.22 billion to focus on AI-enabled initiatives.

AstraZeneca agrees to research deal worth up to $5.22 billion with CSPC

Proactive Investors

Leading bank sees AstraZeneca upside seen in hypertension drug, tempers lung cancer hopes

UBS has reiterated its 'buy' rating on AstraZeneca PLC (LSE:AZN) with a 12-month price target of 14,200p, offering potential upside of just over 30% from the current share price of 10,907p. The focus is on two high-profile drug candidates with contrasting outlooks.

Leading bank sees AstraZeneca upside seen in hypertension drug, tempers lung cancer hopes

Zacks Investment Research

Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term

AstraZeneca CEO: We totally agree with President Trump on this

AstraZeneca CEO Pascal Soriot unpacks President Donald Trump's drug cost cut executive order on 'The Claman Countdown.' #foxbusiness #health #trump #maha

AstraZeneca CEO: We totally agree with President Trump on this

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO

Zacks Investment Research

Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors

Astrazeneca (AZN) closed the most recent trading day at $71.93, moving -1.24% from the previous trading session.

Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors

CNBC Television

AstraZeneca CEO Pascal Soriot on breast cancer drug trial

Pascal Soriot, CEO of AstraZeneca, said on Monday that he sees the pharma company's breast cancer blood test, which tracks signs of returning cancer, as "the future of cancer treatment."

AstraZeneca CEO Pascal Soriot on breast cancer drug trial

See News Rankings

Charts implemented using Lightweight Charts™